Tag: CytoReason

[CytoReason in The Times of Israel] Japanese pharmaceutical firm taps Israel’s CytoReason for AI drug development

CytoReason, an Israeli startup that uses artificial intelligence to build digital models of the human immune system and diseases to speed up drug development, said on Thursday that it was partnering with Japan’s Summit Pharmaceuticals International (SPI) to integrate its machine learning platform into the Japanese clinical drug discovery sector. Read...

Read More

[CytoReason in Yahoo Finance] CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms

TEL AVIV, Israel, June 17, 2021 /PRNewswire/ — CytoReason, an AI company developing a computational disease model of the human body for clinical drug development, today announced the initiation of a project with French global biopharmaceutical company Sanofi, which will utilize its cell-centered models and deconvolution techniques to suggest mechanistic insights for each asthma endotype. Read...

Read More

Latest from Twitter